Related Experiment Video
Updated: Oct 8, 2025
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
Published on: July 5, 2019
Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients
Richard Hoey1, Eva Sharpe1, Angela Kukula1
1The Institute of Cancer Research, London, UK.
Abstract:
New discoveries and technologies are driving major advances in our understanding of cancer and underpinning a new era of precision medicine and immunotherapy. However, advances in treatment have been uneven: whereas survival rates for some common cancers are improving rapidly, for others there has been much less progress. In addition, healthcare systems are finding it difficult to provide access to expensive new treatments. There is an urgent need for imaginative policy solutions to incentivise the creation of novel therapies that address the full range of cancer-causing mechanisms. We have worked with organisations across the medical research community to develop consensus statements on how to enhance access to innovative cancer drugs. Here, we present our reflections on these statements.
Insights
Advances in cancer research offer new precision medicine and immunotherapy treatments. However, uneven progress and high costs necessitate policy solutions to improve access to innovative cancer therapies for all patients.
Area of Science:
- Oncology
- Translational Medicine
- Health Policy
Background:
- Cancer research is rapidly advancing, leading to new precision medicine and immunotherapy strategies.
- Treatment progress for various cancers is inconsistent, with some showing significant survival improvements while others lag.
- Healthcare systems face challenges in providing access to costly novel cancer therapies.
Purpose of the Study:
- To address the urgent need for policy solutions that incentivize the development of novel cancer therapies.
- To enhance access to innovative cancer drugs by developing consensus statements with the medical research community.
Main Methods:
- Collaborative development of consensus statements with organizations across the medical research community.
- Analysis of current challenges in cancer treatment accessibility and innovation.
- Reflection on policy strategies to incentivize novel therapy creation.
Main Results:
- Identification of uneven progress in cancer treatment across different cancer types.
- Recognition of healthcare system barriers to accessing expensive new cancer treatments.
- Formulation of consensus statements aimed at improving access to innovative cancer drugs.
Conclusions:
- Innovative policy solutions are crucial to incentivize the development of novel cancer therapies.
- Enhancing access to cutting-edge cancer treatments requires a coordinated approach involving the medical research community and policymakers.
- Addressing the full spectrum of cancer-causing mechanisms through new therapies is essential for equitable patient outcomes.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis